Product Description
Mechanisms of Action: ACHE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Injection
FDA Designation: *
Approval Status: Approved
Approved Countries: Colombia | Germany | India | Indonesia | New Zealand | Pakistan | Peru | Philippines | Portugal | Taiwan | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Ocugenix Corporation
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Neovascular age-related macular degeneration|Wet Macular Degeneration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| OCU-10-C-110-CS101 | P1 |
Recruiting |
Wet Macular Degeneration|Neovascular age-related macular degeneration |
2026-11-30 |
50% |
2025-03-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/04/2025 |
News Article |
Cognex Announces Participation at Upcoming Investor Conferences |
|
11/03/2025 |
News Article |
AI in Food Processing Market Size to Reach USD 138.26 Billion by 2034, Driven by Rising Automation and Safety Demands |
|
10/28/2025 |
News Article |
Cognex Introduces the Solutions Experience (SLX) Logistics Portfolio |
|
10/21/2025 |
News Article |
InventHelp Inventor Develops Improved Garden Tool (CNC-1108) |